TERT and hepatocellular carcinoma: Distinct from previous drug development for HCC through targeting the telomerase activation function of TERT,38, 39, 40 PLK1 inhibitor is screened on the basis of the single nucleotide mutation in TERT promoter rather than TERT itself, which may have some potential adverse effects because of the high telomerase activity in rapidly growing cells such as germ cells, immune cells and stem cells.41, 42, 43